Records ?

Pediatric Intestine Transplant Recipient Follow-Up Worksheet

FORM APPROVED: O.M.B. NO. 0915-0157 Expiration Date: 10/31/2010

Note: These worksheets are provided to function as a guide to what data will be required in the online TIEDI® application. Currently in the worksheet, a red asterisk is displayed by fields that are required, independent of what other data may be provided. Based on data provided through the online TIEDI® application, additional fields that are dependent on responses provided in these required fields may become required as well. However, since those fields are not required in every case, they are not marked with a red asterisk.

Recipient Information

Name:	**DOB:**
SSN:	**Gender:**
HIC:	**Tx Date:**
Previous Follow-Up:	**Previous Px Stat Date:**

Transplant Discharge Date: [_____]

State of Permanent Residence: * [_____]

Zip Code: * [_____] - [_____]

Provider Information

Recipient Center:

Followup Center:

Physician Name: * [_____]

NPI#: * [_____]

Follow-up Care Provided By: *
- ○ Transplant Center
- ○ Non Transplant Center Specialty Physician
- ○ Primary Care Physician
- ○ Other Specify

Specify: [_____]

Donor Information

UNOS Donor ID #:

Donor Type:

Patient Status

Date: Last Seen, Retransplanted or Death * [_____]

Patient Status: *
- ○ LIVING
- ○ DEAD

	○ **RETRANSPLANTED**

Primary Cause of Death:	[_____]
Specify:	[_____]

Contributory Cause of Death:	[_____]
Specify:	[_____]

Contributory Cause of Death:	[_____]
Specify:	[_____]

Hospitalizations:

Has the patient been hospitalized since the last patient status date: ✽	○ YES ○ NO ○ UNK
Number of Hospitalizations:	[_____] ST= [_____]

Noncompliance:

Was there evidence of noncompliance with immunosuppression medication during this follow-up period that compromised the patient's recovery:	○ YES ○ NO ○ UNK

Functional Status: ✽	[_____]

Cognitive Development: ✽	○ **Definite Cognitive delay/impairment**
	○ **Probable Cognitive delay/impairment**
	○ **Questionable Cognitive delay/impairment**
	○ **No Cognitive delay/impairment**
	○ **Not Assessed**

Motor Development: ✽	○ **Definite Motor delay/impairment**
	○ **Probable Motor delay/impairment**
	○ **Questionable Motor delay/impairment**
	○ **No Motor delay/impairment**
	○ **Not Assessed**

Academic Progress *	○ Within One Grade Level of Peers
	○ Delayed Grade Level
	○ Special Education
	○ Not Applicable < 5 years old/ High School graduate or GED
	○ Status Unknown

Academic Activity Level *	○ Full academic load
	○ Reduced academic load
	○ Unable to participate in academics due to disease or condition
	○ Not Applicable < 5 years old/ High School graduate or GED
	○ Status Unknown

Primary Insurance at Follow-up: * [   ]

    Specify: [   ]

Clinical Information

Date of Measurement: [   ]

Height: * [   ] ft. [   ] in. [   ] cm **ST=** [   ]

Weight: * [   ] lbs. [   ] kg **ST=** [   ]

BMI: kg/m^2

Graft Status: *   ○ Functioning ○ Failed

If death is indicated for the recipient, and the death was a result of some other factor unrelated to graft failure, select Functioning.

    TPN Dependent: ○ YES ○ NO

    IV Dependent: ○ YES ○ NO

    Oral Feeding: ○ YES ○ NO

    Tube Feeding: ○ YES ○ NO

Date of Failure: [   ]

Primary Cause of Failure: [   ]

    Other, Specify: [   ]

Diabetes onset during the follow-up period: ✱ ○ YES ○ NO ○ UNK

    Insulin dependent: ○ YES ○ NO ○ UNK

Most Recent Lab date: [   ]

Total Bilirubin: ✱ [   ] mg/dl   ST= [   ]

Serum Albumin: [   ] mg/dl   ST= [   ]

Serum Creatinine: ✱ [   ] mg/dl   ST= [   ]

Did patient have any acute rejection episodes during the follow-up period: ✱

○ Yes, at least one episode treated with anti-rejection agent

○ Yes, none treated with additional anti-rejection agent

○ No

○ Unknown

Was biopsy done to confirm acute rejection:

○ Biopsy not done

○ Yes, rejection confirmed

○ Yes, rejection not confirmed

○ Unknown

Post Transplant Malignancy: ✱ ○ YES ○ NO ○ UNK

    Donor Related: ○ YES ○ NO ○ UNK

    Recurrence of Pre-Tx Tumor: ○ YES ○ NO ○ UNK

    De Novo Solid Tumor: ○ YES ○ NO ○ UNK

    De Novo Lymphoproliferative disease and Lymphoma: ○ YES ○ NO ○ UNK

Treatment

Biological or Anti-viral therapy: ○ YES   ○ NO   ○ Unknown/Cannot disclose

If Yes, check all that apply:

☐ Acyclovir (Zovirax)

☐ Cytogam (CMV)

☐ Gamimune

☐ Gammagard

☐ Ganciclovir (Cytovene)

☐ Valgancyclovir (Valcyte)

☐ HBIG (Hepatitis B Immune Globulin)

☐ Flu Vaccine (Influenza Virus)

☐ Lamivudine (Epivir) (for treatment of Hepatitis B)

☐ Valacyclovir (Valtrex)

☐ Other, Specify

Specify: *   [   ]

Specify: [   ]

Other therapies: ○ YES   ○ NO

If Yes, check all that apply:

☐ Photopheresis

☐ Plasmapheresis

☐ Total Lymphoid Irradiation (TLI)

Immunosuppressive Information

Previous Validated Maintenance Follow-Up Medications:

Previous Validated Maintenance Follow-Up Medications:

Were any medications given during the follow-up period for maintenance:

○ Yes, same as validated TRR form

○ Yes, same as previous validated report

○ Yes, but different than previous validated report

○ None given

Did the physician discontinue all maintenance immunosuppressive medications:	○ YES ○ NO		

Did the patient participate in any clinical research protocol for immunosuppressive medications:	○ YES ○ NO		
Specify: *			

Immunosuppressive Medications

View Immunosuppressive Medications

Definitions Of Immunosuppressive Follow-Up Medications

For each of the immunosuppressant medications listed, check **Previous Maintenance (Prev Maint)**, **Current Maintenance (Curr Maint)** or **Anti-rejection (AR)** to indicate all medications that were prescribed for the recipient during this follow-up period, and for what reason. If a medication was not given, leave the associated box(es) blank.

Previous Maintenance (Prev Maint) includes all immunosuppressive medications given during the report period, which covers the period from the last clinic visit to the current clinic visit, *for varying periods of time which may be either long-term or intermediate term with a tapering of the dosage until the drug is either eliminated or replaced by another long-term maintenance drug* (example: Prednisone, Cyclosporine, Tacrolimus, Mycophenolate Mofetil, Azathioprine, or Rapamycin). This does not include any immunosuppressive medications given to treat rejection episodes.

Current Maintenance (Curr Maint) includes all immunosuppressive medications given at the current clinic visit to begin in the next report *for varying periods of time which may be either long-term or intermediate term with a tapering of the dosage until the drug is either eliminated or replaced by another long-term maintenance drug* (example: Prednisone, Cyclosporine, Tacrolimus, Mycophenolate Mofetil, Azathioprine, or Rapamycin). This does not include any immunosuppressive medications given to treat rejection episodes.

Anti-rejection (AR) immunosuppression includes all immunosuppressive medications given for the purpose of treating an acute rejection episode since the last clinic visit (example: Methylprednisolone, Atgam, OKT3, or Thymoglobulin). When switching maintenance drugs (example: from Tacrolimus to Cyclosporine; or from Mycophenolate Mofetil to Azathioprine) because of rejection, the drugs <u>should not</u> be listed under AR immunosuppression, but <u>should be</u> listed under maintenance immunosuppression.
Note: The Anti-rejection field refers to any anti-rejection medications since the last clinic visit, not just at the time of the current clinic visit.

If an immunosuppressive medication other than those listed is being administered (e.g., new monoclonal antibodies), select Previous Maint, or Current Maint, or AR next to Other Immunosuppressive Medication field, and enter the full name of the medication in the space provided. **Do not list non-immunosuppressive medications.**

	Prev Maint	Curr Maint	AR
Steroids (Prednisone,Methylprednisolone,Solumedrol,Medrol,Decadron)	☐	☐	☐
Atgam (ATG)	☐	☐	☐
OKT3 (Orthoclone, Muromonab)	☐	☐	☐
Thymoglobulin	☐	☐	☐
Simulect - Basiliximab	☐	☐	☐
Zenapax - Daclizumab	☐	☐	☐
Azathioprine (AZA, Imuran)	☐	☐	☐
EON (Generic Cyclosporine)	☐	☐	☐
Gengraf (Abbott Cyclosporine)	☐	☐	☐

		Prev Maint	Curr Maint	AR
Other generic Cyclosporine, specify brand:		☐	☐	☐
Neoral (CyA-NOF)		☐	☐	☐
Sandimmune (Cyclosporine A)		☐	☐	☐
CellCept (Mycophenolate Mofetil; MMF)		☐	☐	☐
Generic MMF (Generic CellCept)		☐	☐	☐
Prograf (Tacrolimus, FK506)		☐	☐	☐
Generic Tacrolimus (Generic Prograf)		☐	☐	☐
Modified Release Tacrolimus FK506E (MR4)		☐	☐	☐
Sirolimus (RAPA, Rapamycin, Rapamune)		☐	☐	☐
Myfortic (Mycophenolate Sodium)		☐	☐	☐

Other Immunosuppressive Medications

		Prev Maint	Curr Maint	AR
Campath - Alemtuzumab (anti-CD52)		☐	☐	☐
Cyclophosphamide (Cytoxan)		☐	☐	☐
Leflunomide (LFL, Arava)		☐	☐	☐
Methotrexate (Folex, PFS, Mexate-AQ, Rheumatrex)		☐	☐	☐
Other Immunosuppressive Medication, Specify		☐	☐	☐
Rituximab		☐	☐	☐

Investigational Immunosuppressive Medications

		Prev Maint	Curr Maint	AR
Everolimus (RAD, Certican)		☐	☐	☐
Other Immunosuppressive Medication, Specify		☐	☐	☐

UNOS View Only

Comments: